Medivation (MDVN) Receives Price Target

Medivation (MDVN) : Average target price received by Medivation (MDVN) is $71.82 with an expected standard deviation of $12.35. The most aggressive target on the stock is $82, whereas the most downbeat target is $40. 14 financial analysts are currently covering the stock.

Medivation (MDVN) : 3 brokerage houses believe that Medivation (MDVN) is a Strong Buy at current levels. 11 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Medivation (MDVN). Zacks Investment Research suggests a Strong Sell with a rank of 5.The median of all the 14 Wall Street Analysts endorse the stock as a Hold with a rating of 2.57.


Also, Equity Analysts at the Brokerage Firm, Citigroup, downgrades their rating on the shares of Medivation (NASDAQ:MDVN). Citigroup has a Hold rating on the shares. Previously, the analysts had a Buy rating on the shares. As per the latest research report, the brokerage house raises the price target to $81.5 per share from a prior target of $73. The rating by the firm was issued on August 23, 2016.

Medivation (NASDAQ:MDVN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $80.45 and $80.45 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $80.98. The buying momentum continued till the end and the stock did not give up its gains. It closed at $80.93, notching a gain of 0.46% for the day. The total traded volume was 6,700,788 . The stock had closed at $80.56 on the previous day.

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.